Top

Published in:

01-01-2019 | Original Article

Pim-2 Cooperates with Downstream Factor XIAP to Inhibit Apoptosis and Intensify Malignant Grade in Prostate Cancer

Authors: Ke Ren, Xin Gou, Mingzhao Xiao, Weiyang He, Jian Kang

Published in: Pathology & Oncology Research | Issue 1/2019

Abstract

To find the exact downstream effector of Pim-2 pathway in prostate cancer cells, and to determine the means by which it affects prostate cancer. XIAP, Pim-2 and p-eIF4B expressions were detected in PCA and BPH tissues. Then the Pim-2 and XIAP expressions were manipulated using transfection or RNAi in prostatic cells. Finally, Pim-2/eIF4B/XIAP levels were examined in PCA tissues with different clinicopathologic features. XIAP was significantly higher in PCA than in BPH tissues. When Pim-2 was transfected into noncancerous prostate epithelial cells RWPE-1, Pim-2, p-eIF4B and XIAP were all significantly increased and the apoptosis rate was significantly decreased. When XIAP was transfected into RWPE-1 cells, XIAP was significantly increased with no impact on Pim-2, p-eIF4B and the apoptosis rate. When Pim-2 SiRNA was transfected into prostate cancer cells PC-3, Pim-2, p-eIF4B and XIAP were significantly decreased and the apoptosis rate was significantly increased. When XIAP SiRNA was transfected into PC-3 cells, XIAP was significantly decreased with no impact on Pim-2, p-eIF4B and apoptosis rate. Pim-2, p-eIF4B and XIAP were all significantly higher in PCA tissues with GS ≥8 than those with GS ≤7. XIAP is the downstream factor of Pim-2 pathway in prostate cancer cells. Pim-2 and XIAP cooperate in inhibiting the apoptosis of prostate cancer cells. The activation of Pim-2 pathway may predict higher GS in prostate cancer.

Available only for authorised users

White E (2003) The Pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev 17(15):1813–1816. https://doi.org/10.1101/gad.1123103 CrossRefPubMed

Ren K, Gou X, Xiao M, Wang M, Liu C, Tang Z, He W (2013) The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B. Prostate 73(13):1462–1469. https://doi.org/10.1002/pros.22693 CrossRefPubMed

Yang J, Wang J, Chen K, Guo G, Xi R, Rothman PB, Whitten D, Zhang L, Huang S, Chen JL (2013) eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes. Cancer Res 73(15):4898–4908. https://doi.org/10.1158/0008-5472.CAN-12-4277 CrossRefPubMed

Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs BF, Svitkin Y, Sonenberg N (2010) Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 30(6):1478–1485. https://doi.org/10.1128/MCB.01218-09 CrossRefPubMedPubMedCentral

Swanson GP, Basler JW (2010) Prognostic factors for failure after prostatectomy. J Cancer 2:1–19 PMID: 21197260CrossRefPubMedPubMedCentral

Mand G-H, Meier P (2010) IAPs: from caspase inhibitors to modulators of nf-kappab, inflammation and cancer. Nat Rev Cancer 10(8):561–574. https://doi.org/10.1038/nrc2889 CrossRef

Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V (2011) Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 118(3):693–702. https://doi.org/10.1182/blood-2010-12-323022 CrossRefPubMedPubMedCentral

Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V (2009) Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114(19):4150–4157. https://doi.org/10.1182/blood-2009-03-212852 CrossRefPubMedPubMedCentral

Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, Rowley D (2004) Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64(17):6082–6090. https://doi.org/10.1158/0008-5472.CAN-04-0838 CrossRefPubMed

10.

Kapelko-Słowik K, Urbaniak-Kujda D, Wołowiec D, Jaźwiec B, Dybko J, Jakubaszko J, Słowik M, Kuliczkowski K (2013) Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival. Postepy Hig Med Dosw (Online) 67:553–559 PMID: 23752607CrossRef

11.

Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K, Miki H, Nakamura S, Harada T, Fujii S, Kagawa K, Endo I, Yata K, Sakai A, Ozaki S, Matsumoto T, Abe M (2011) The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 25(7):1182–1188. https://doi.org/10.1038/leu.2011.60 CrossRefPubMed

12.

Ren K, Zhang W, Shi Y, Gong J (2010) Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway. Pathol Oncol Res 16(2):229–237. https://doi.org/10.1007/s12253-009-9215-4 CrossRefPubMed

13.

Park YH, Seo SY, Lee E, JH K, Kim HH, Kwak C (2013) Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor-κB pathway. J Urol 189(4):1547–1552. https://doi.org/10.1016/j.juro.2012.10.030 CrossRefPubMed

14.

Kim HR, Park CG, Jung JY (2014) Acacetin (5,7-dihydroxy-4′-methoxyflavone) exhibits in vitro and in vivo anticancer activity through the suppression of NF-κB/Akt signaling in prostate cancer cells. Int J Mol Med 33(2):317–324. https://doi.org/10.3892/ijmm.2013.1571 CrossRefPubMed

15.

Zhang P, Chen L, Song Y, Li X, Sun Y, Xiao Y, Xing Y (2016) Tetraiodothyroacetic acid and transthyretin silencing inhibit pro-metastatic effect of L-thyroxin in anoikis-resistant prostate cancer cells through regulation of MAPK/ERK pathway. Exp Cell Res 347(2):350–359. https://doi.org/10.1016/j.yexcr.2016.08.019 CrossRefPubMed

16.

Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, Glinsky GV (2005) Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 65:2378–2386. https://doi.org/10.1158/0008-5472.CAN-04-2649 CrossRefPubMed

17.

Nomura T, Yamasaki M, Nomura Y, Mimata H (2005) Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 14:993–997 PMID: 16142363PubMed

18.

Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC (2000) Expressionand prognostic signicance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6:1796–1803 PMID: 10815900PubMed

19.

Rodríguez-Berriguete G, Torrealba N, Ortega MA, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Guil-Cid M, Fraile B, Royuela M (2015) Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy. BMC Cancer 15:809. https://doi.org/10.1186/s12885-015-1839-z CrossRefPubMedPubMedCentral

20.

Seligson DB, Hongo F, Huerta-Yepez S, Mizutani Y, Miki T, Yu H, Horvath S, Chia D, Goodglick L, Bonavida B (2007) Expression of x-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res 13(20):6056–6063. https://doi.org/10.1158/1078-0432.CCR-07-0960 CrossRefPubMed

21.

Hwang C, Oetjen KA, Kosoff D, Wojno KJ, Albertelli MA, Dunn RL, Robins DM, Cooney KA, Duckett CS (2008) X-linked inhibitor of apoptosis deficiency in the tramp mouse prostate cancer model. Cell Death Differ 15(5):831–840. https://doi.org/10.1038/cdd.2008.15 CrossRefPubMedPubMedCentral

22.

Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FA, Pinedo HM, van Tinteren H, Giaccone G (2001) Expression of x-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 7(8):2468–2474 PMID: 11489828PubMed

23.

Aggarwal BB, Ichikawa H (2005) Molecular targets and anticancer potential of indole-3 carbinol and its derivatives. Cell Cycle 4(9):1201–1215. https://doi.org/10.4161/cc.4.9.1993 CrossRefPubMed

24.

Kashkar H (2010) X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin Cancer Res 16(18):4496–4502. https://doi.org/10.1158/1078-0432.CCR-10-1664 CrossRefPubMed

Title: Pim-2 Cooperates with Downstream Factor XIAP to Inhibit Apoptosis and Intensify Malignant Grade in Prostate Cancer
Authors: Ke Ren
Xin Gou
Mingzhao Xiao
Weiyang He
Jian Kang
Publication date: 01-01-2019
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 1/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0353-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Genetic Variations of DNA Repair Genes in Breast Cancer

Long Non-Coding RNA SPRY4-IT1 Can Predict Poor Prognosis in Digestive System Malignancies: a Meta-Analysis

A Potential Role for Green Tea as a Radiation Sensitizer for Prostate Cancer

Cerebrovascular Complications and Polycythaemia Vera

Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma

Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer